Inactive Instrument

Biovica International AB (publ) Share Price Nasdaq Stockholm

Equities

SE0008613731

Biotechnology & Medical Research

Financials

Sales 2024 * 10M 925K 77.07M Sales 2025 * 116M 10.73M 894M Capitalization 135M 12.51M 1.04B
Net income 2024 * -115M -10.63M -886M Net income 2025 * -60M -5.55M -462M EV / Sales 2024 * 6.18 x
Net cash position 2024 * 73.52M 6.8M 567M Net cash position 2025 * 45.95M 4.25M 354M EV / Sales 2025 * 0.77 x
P/E ratio 2024 *
-0.22 x
P/E ratio 2025 *
-0.56 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.54%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Biovica International AB (publ)

Managers TitleAgeSince
Chief Executive Officer 54 01/10/01
Director of Finance/CFO 59 01/23/01
Chief Tech/Sci/R&D Officer 45 01/22/01
Members of the board TitleAgeSince
Chairman 64 20/19/20
Director/Board Member 61 01/20/01
Director/Board Member 68 01/16/01
More insiders
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Calendar
More about the company